The research described in this thesis focused on identifying novel drug targets and synergistic combinations for triple-negative breast cancer (TNBC), a virulent subtype of breast cancer with a dismal prognosis and limited therapeutic options.

Triple-negative breast cancer (TNBC) constitutes a small subtype (~15%) of breast cancer, but causes the majority of breast cancer-related deaths.

Inactivating mutations in BRCA1 or BRCA2 genes predispose to several types of cancer.

PhD Defence

PhD Defence

PhD Defence

PhD Defence

PhD Defence

PhD Defence

PhD Defence

In this thesis, we used genetically engineered mouse models to identify genes and pathways that are involved in ILC formation and in the development of resistance to FGFR-targeted therapy.

Chemotherapy that does nothing until you irradiate it with light. Sylvestre Bonnet receives a Vici grant of 1.5 million euros for the development of this treatment. The Leiden chemist wants to build a new molecule to fight tumours that are at the time still difficult to treat.

With cancer, a person’s body cells grow uncontrollably. Putting together a detailed picture of how this comes about makes it possible to develop efficient therapies. Researchers at the Leiden University Medical Centre (LUMC) and Leiden University are working together to gain a better understanding…

Exploiting metabolic vulnerabilities to identify anticancer compounds in zebrafish synthetic lethality screens.

Decision support tool for cell therapy commercialization and business development

How effective is eye movement desensitization and reprocessing therapy in targeting epilepsy-related anxiety?

Promotor: Prof.dr. J. Kuiper, Co-Promotor: S.C.A. de Jager

Strengthening a cancer patient's own immune system so that the body itself can better destroy cancer cells. This is at the heart of immunotherapy, the most promising progress in cancer treatment in recent years. In order to drive this development further, the Netherlands Cancer Institute-Antoni van…

Is translocation of nucleases possible via Agrobacterium T4SS and is it efficient enough for mutagenesis?

Tiny selenium particles could have a therapeutic effect on ischemic brain strokes by promoting the recovery of brain damage. Pharmacologists, including Alireza Mashaghi from the Leiden Academic Centre for Drug Research discovered that selenium nanoparticles inhibit molecular mechanisms that are responsible…

Prediction of human (CNS) target site concentrations in health and disease In the vision of Prof. de Lange we will only be able to predict human (central nervous system, CNS) target site concentrations and effects if we perform systematic, condition-dependent, integrative, and strictly quantitative…

Cancer represents a formidable current and future global health challenge. The LUMC medical research profile Cancer Pathogenesis and Therapy charges this challenge by developing and implementing innovative patient-tailored, multimodal diagnostic methods and treatment modalities.

How to identify patients at risk of developing devastating, metastatic disease and facilitate the development of personalised treatment for prostate cancer patients?

Inflammatory skin diseases such as psoriasis and atopic dermatitis can severely impact both the physical and social aspect of a patient’s life. Aberrant inflammatory responses are thought to be a major causative factor in these disorders, but an abundance of different factors contribute to the development…

Drug development is a time- and resource-consuming process that starts with the discovery and validation of a (protein) target that contributes to pathogenesis or disease progression.

Esmee Koedoot is our Leiden Academic Centre for Drug Research's nominee for the C.J. Kok Jury Award 2019.

We are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.

In order to optimize treatment, it is necessary to closely monitor and manage the patient’s health status by means of ‘precision diagnostics and targeted therapy’. The specialisation combines the techniques and applications of these sensing (monitoring) and stimulation techniques. The field of sensing…

More and more medicines are becoming available that target a tumour’s specific traits. The use of chemotherapy is continually undergoing improvement.

Efficient gene-targeting during meiosis

Promotores: Prof.dr. H. S. Overkleeft, Prof.dr. G. A. van der Marel

Can drugs that target host signaling pathways be used to eradicate antibiotic-resistant bacteria?

Can we bring novel treatment options to the clinic for UM patients with liver metastases?

An integrated approach for the simultaneous prediction of polypharmacology and binding affinity/potency of small molecules.

We aim to gain a better understanding of the natural disease progression of ALS in order to improve clinical trial design and analysis and to support drug discovery and clinical development of new drugs.

Lecture, Sociolinguistics Series

Ontwikkeling van resistentie tegen antibiotica kan optreden als patiënten onnodig of te lang met antibiotica behandeld worden. Diagnostiek waarmee snel een bacteriële infectie vastgesteld kan worden, of de response op antibiotica bepaald kan worden, zijn daarom belangrijk om therapie te optimaliseren…

Stem cells can be differentiated into insulin-producing cells.

In the research programme Drug Discovery & Safety, we are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.

Dendritic cells (DC) play a prominent role in the priming of CD8(+) T cells. Vaccination is a promising treatment to boost tumor-specific CD8(+) T cells which is crucially dependent on adequate delivery of the vaccine to DC.

PhD Defence

As of April 1, 2018, Erik Danen has been appointed as Professor of Cancer drug target discovery at the Leiden Academic Centre for Drug Research (LACDR). His discipline is cell biology of cancer, in which he focuses on the mechanisms underlying metastasis and therapy resistance.

In this research group, headed by Bob Van de Water, cell signaling programs that underlie adverse drug reactions as well as cancer development and progression are unraveled. Adverse drug reactions involve cell injury in critical target organ cells which leads to the activation of cellular stress response…

-

We focus on a better understanding of the mechanisms of cancer drug resistance and metastasis.